The Mayo Clinic Positron Emmission Tomography (PET) Radiochemistry Facility in Rochester, Minnesota has unveiled a new imaging agent, approved by the U.S. Food and Drug Administration, to aid in detecting recurring prostate cancer.
Known as Choline C 11, "the injected substance helps produce an image that allows doctors to identify tissues to test for the disease." While the FDA warns that this PET test is not intended to act as a substitute for actual tissue testing, the side effects of Choline C11 are relatively minor, namely a mild skin reaction at the injection site.
To read more about Choline C 11, click here.
No comments:
Post a Comment